Antonia SJ et al. Overall survival with durvalumab after chemoradiotherapy in Stage III NSCLC. N Engl J Med 2018;379:2342-50. Abstract
Antonia SJ et al. Durvalumab after chemoradiotherapy in Stage III non-small-cell lung cancer. N Engl J Med 2017;377(20):1919-29. Abstract
Bradley JD et al. Long-term results of RTOG 0617: A randomized phase 3 comparison of standard dose versus high dose conformal chemoradiation therapy +/- cetuximab for stage III NSCLC. Int J Radiat Oncol Biol Phys 2017;99(2):S105. Abstract
Cavanna L et al. Immune checkpoint inhibitors in EGFR-mutation positive TKI-treated patients with advanced non-small-cell lung cancer network meta-analysis. Oncotarget 2019;10(2):209-15. Abstract
Cheema PK et al. Perspectives on treatment advances for stage III locally advanced unresectable non-small-cell lung cancer. Curr Oncol 2019;26(1):37-42. Abstract
Dudley JC et al. Microsatellite instability as a biomarker for PD-1 blockade. Clin Cancer Res 2016;22(4):813-20. Abstract
Faivre-Finn C et al. Durvalumab after chemoradiotherapy in stage III NSCLC: 4-year survival update from the phase III PACIFIC trial. ESMO 2020;Abstract LBA49.
Forde P et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med 2018;378(21):1976-86. Abstract
Gray JE et al. Three-year overall survival with durvalumab after chemoradiotherapy in stage III NSCLC — Update from PACIFIC. J Thorac Oncol 2020;15(2):288-93. Abstract
Hanna N et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: The Hoosier Oncology Group and US Oncology. J Clin Oncol 2008;26(35):5755-60. Abstract
Hui R et al. Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): A randomised, controlled, phase 3 study. Lancet Oncol 2019;20(12):1670-80. Abstract
Pakkala S, Ramalingam SS. Personalized therapy for lung cancer: Striking a moving target. JCI Insight 2018;3(15):e120858. Abstract
Rizvi H et al. Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing. J Clin Oncol 2018;36(7):633-41. Abstract
Shaverdian N et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: A secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol 2017;18(7):895-903. Abstract
Skrzypski M et al. Consolidation systemic treatment after radiochemotherapy for unresectable stage III non-small cell lung cancer. Cancer Treat Rev 2018;66:114-21. Abstract
Walters S et al. Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: A population-based study, 2004-2007. Thorax 2013;68(6):551-64. Abstract
Yoon SM et al. Therapeutic management options for stage III non-small cell lung cancer. World J Clin Oncol 2017;8(1):1-20. Abstract